Category: Zacks Small Cap Research

1 2 3 28 10 / 279 POSTS
By David Bautz, PhDNASDAQ:TNXPREAD THE FULL TNXP RESEARCH REPORTBusiness UpdateNew Phase 3 Trial for TNX-102 SL to Initiate in 1Q19On October 31, 2018, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced that the company will be initiating a ...
By Steven Ralston, CFANASDAQ:MNGAREAD THE FULL RESEARCH REPORT HEREMagneGas Expanding in Domestic Industrial Gas Business & Pursuing European GrantsMagneGas Applied Technology Solutions (NASDAQ:MNGA) produces, sells and distributes MagneGas2®, a ...
By Brian Marckx, CFAQ3 Financial Results and Operational UpdateNASDAQ:DRRXREAD THE FULL RESEARCH REPORT HERELast week Durect (NASDAQ:DRRX) reported financial results for their third quarter ending September 30th and provided a business update.  Relat ...
By Lisa ThompsonNASDAQ:CIDMREAD THE FULL RESEARCH REPORT HERERevenues for the quarter ending September 30, 2018 came in significantly above expectations at $13.7 million versus $16.3 million a year ago, declining 16%. $7.5 million came from the legac ...
By David Bautz, PhDNASDAQ:ORMPREAD THE FULL RESEARCH REPORT HEREBusiness UpdateOramed Pharmaceuticals Inc. (NASDAQ:ORMP) is a biotechnology company with a proprietary oral protein delivery platform technology. The lead development candidate is ORMD-0 ...
By John Vandermosten, CFANASDAQ:ATXIAvenue Therapeutics (NASDAQ:ATXI) announced an acquisition agreement with InvaGen Pharmaceuticals to acquire a 33.3% stake in the company for $35 million to be followed by a second stage closing in 2021 which will ...
By David Bautz, PhDNASDAQ:VKTXREAD THE FULL VKTX RESEARCH REPORTBusiness UpdatePhase 2 Data for VK2809 Presented at AASLDOn November 12, 2018, Viking Therapeutics, Inc. (NASDAQ:VKTX) presented results from the Phase 2 trial of VK2809, the company’s t ...
NYSE:NNVCIntroductionNanoViricides Inc. (NYSE:NNVC) is an early stage nano-pharmaceutical company that was first listed in 2005 and became a reporting company the following year. The company is involved in discovering and developing therapeutics for ...
By Brian Marckx, CFANASDAQ:MTBCREAD THE FULL MTBC RESEARCH REPORTQ3 2018 Results: Medical Transcription Billing Corp (NASDAQ:MTBC) reported financial results for their third quarter 2018 and provided a business update. This was the first quarter with ...
By David Bautz, PhDNASDAQ:CFRXREAD THE FULL CFRX RESEARCH REPORTBusiness UpdatePhase 2 Trial of CF-301 Fully EnrolledIn September 2018, ContraFect Corp. (NASDAQ:CFRX) announced that the Phase 2 trial of CF-301 (exebacase) is fully enrolled. CF-301 is ...
1 2 3 28 10 / 279 POSTS